# Methylene Blue Treatment of COVID-19

> **NCT04635605** · PHASE2 · COMPLETED · sponsor: **Fondazione Epatocentro Ticino** · enrollment: 29 (actual)

## Conditions studied

- SARS-CoV2

## Interventions

- **DRUG:** Methylene Blue
- **DRUG:** Control Test

## Key facts

- **NCT ID:** NCT04635605
- **Lead sponsor:** Fondazione Epatocentro Ticino
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-05
- **Primary completion:** 2021-08-13
- **Final completion:** 2021-08-13
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635605, "Methylene Blue Treatment of COVID-19". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT04635605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*